Le Lézard
Classified in: Health, Business
Subjects: SVY, ECO, EGV

2022 Marked a Record for German R&D Investments


BERLIN, March 19, 2024 /PRNewswire/ -- EUR 121.4 billion was spent in Germany on research and development ? more than ever before in a single year.

According to the Federal Statistical Office, the amount of money devoted to R&D rose by seven percent in 2022, reaching an all-time high. The figures include commercial, university and non-university research.

R&D investments by businesses grew by eight percent, reaching EUR 81.8 billion. That's more than two-thirds of all the money invested in R&D.

Expenditures for research and development in Germany have amounted to 3.1 percent of GDP since 2020. Germany has exceeded the EU guideline of three percent for R&D investments for the past six years in a row.

"The German government intends to increase the percentage of R&D to GDP to 3.5 percent by 2025," says Robert Hermann, CEO of the German agency for international economic promotion, Germany Trade & Invest. "The growth in this investment shows how much Germany prioritized research and development. It's a central element in Germany's drive to be one of the leading locations for investments in high tech."

Germany Trade & Invest (GTAI) is the economic promotion agency of the Federal Republic of Germany. GTAI supports German companies setting up in foreign markets, promotes Germany as a business location and assists foreign companies setting up shop in Germany.

Contact:

Andreas Bilfinger 

Germany Trade & Invest

T: +49 30200099173

[email protected] 

SOURCE Germany Trade & Invest


These press releases may also interest you

at 08:08
Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q2, 2024. The presentation will be held in English. Time: Wednesday 17 July, 2024 at 10.00 a.m. CET. To attend the conference call, please use this...

at 08:05
Viridian Therapeutics, Inc. (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent...

at 08:01
Neuromod Devices Ltd. (Neuromod), the global medical technology business that created the first and only FDA Approved tinnitus treatment device, Lenire, has today announced the appointment of Tom Maher as General Counsel, effective July 5, 2024....

at 08:00
The "Annual GMP Master Class 2024" training has been added to ResearchAndMarkets.com's offering. cGMPs or Current Good Manufacturing Practices is a general encompassing term for the regulations that the control of all facets of life sciences...

at 08:00
The Canadian Dermatology Association (CDA) is proud to announce this year's recipients of its Member Awards and Public Education Awards, following a detailed review of nominations received by the Membership and Awards Committee using a thorough...

at 08:00
IntelGenx Corp. (the "Company" or "IntelGenx" a subsidiary of IntelGenx Technologies Corp.) , has successfully completed the BUENA Alzheimer's disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to investigate the...



News published on and distributed by: